KEVIN YOUNG Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for KEVIN YOUNG.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of KEVIN YOUNG. KEVIN YOUNG is Chief Operating Officer in GILEAD SCIENCES INC ($GILD) and EVP, Commercial Operations in GILEAD SCIENCES INC ($GILD) and Director in Cortexyme, Inc. ($CRTX).
Latest Insider Trading Transactions of KEVIN YOUNG
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 09 2020 | CRTX | Cortexyme, Inc. | YOUNG KEVIN | Director | Option Exercise | A | 41.73 | 11,029 | 460,240 | 11,029 | |
| Mar 12 2020 | CRTX | Cortexyme, Inc. | YOUNG KEVIN | Director | Buy | P | 17.00 | 30,000 | 510,000 | 30,000 | 0 to 30 K |
| Mar 12 2020 | CRTX | Cortexyme, Inc. | YOUNG KEVIN | Director | Buy | P | 17.00 | 30,000 | 510,000 | 30,000 | 0 to 30 K |
| Feb 23 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 0.00 | 9,460 | 0 | 25,612 | 16.2 K to 25.6 K (+58.57 %) |
| Feb 23 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 62.35 | 340 | 21,198 | 16,152 | 15.8 K to 16.2 K (+2.15 %) |
| Feb 02 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 620 | 0 | 4,092 | |
| Feb 02 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 83.49 | 218 | 18,201 | 15,329 | 15.5 K to 15.3 K (-1.40 %) |
| Feb 02 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 620 | 0 | 15,547 | 14.9 K to 15.5 K (+4.15 %) |
| Feb 02 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 83.80 | 2,259 | 189,304 | 14,927 | 17.2 K to 14.9 K (-13.14 %) |
| Feb 02 2018 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 0.00 | 7,110 | 0 | 17,186 | 10.1 K to 17.2 K (+70.56 %) |
| Nov 13 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 73.02 | 3,422 | 249,874 | 10,076 | 13.5 K to 10.1 K (-25.35 %) |
| Nov 13 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 0.00 | 6,810 | 0 | 13,498 | 6.7 K to 13.5 K (+101.82 %) |
| Aug 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 910 | 0 | 4,712 | |
| Aug 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 72.70 | 453 | 32,933 | 6,688 | 7.1 K to 6.7 K (-6.34 %) |
| Aug 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 910 | 0 | 7,141 | 6.2 K to 7.1 K (+14.60 %) |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 66.92 | 3,460 | 231,543 | 6,231 | 9.7 K to 6.2 K (-35.70 %) |
| May 12 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 0.00 | 6,810 | 0 | 9,691 | 2.9 K to 9.7 K (+236.38 %) |
| Feb 21 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Grant | A | 59.33 | 315 | 18,689 | 2,881 | 2.6 K to 2.9 K (+12.28 %) |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 908 | 0 | 5,622 | |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 66.36 | 317 | 21,036 | 2,566 | 2.9 K to 2.6 K (-11.00 %) |
| Feb 14 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 908 | 0 | 2,883 | 2 K to 2.9 K (+45.97 %) |
| Feb 06 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | A | 72.25 | 115,870 | 8,371,608 | 115,870 | |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | M | 0.00 | 620 | 0 | 6,530 | |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Payment of Exercise | F | 72.82 | 215 | 15,656 | 1,975 | 2.2 K to 2 K (-9.82 %) |
| Feb 03 2017 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Buy | M | 0.00 | 620 | 0 | 2,190 | 1.6 K to 2.2 K (+39.49 %) |
| Jun 14 2016 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | Chief Operating Off ... | Option Exercise | A | 84.45 | 83,880 | 7,083,666 | 83,880 | |
| Feb 04 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | D | 0.00 | 11,130 | 0 | 153,931 | |
| Feb 04 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 0.00 | 2,480 | 0 | 2,480 | |
| Feb 04 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 80.65 | 8,250 | 665,363 | 8,250 | |
| Jan 27 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 107,508 | |
| Jan 27 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 81.44 | 100,000 | 8,144,150 | 216,418 | 316.4 K to 216.4 K (-31.60 %) |
| Jan 27 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.40 | 100,000 | 1,639,500 | 316,418 | 216.4 K to 316.4 K (+46.21 %) |
| Jan 27 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 11,912 | 0 | 216,418 | 204.5 K to 216.4 K (+5.82 %) |
| Jan 27 2014 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 21,334 | 0 | 204,506 | 183.2 K to 204.5 K (+11.65 %) |
| Dec 24 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.40 | 75,000 | 1,229,625 | 207,508 | |
| Dec 24 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 74.19 | 75,000 | 5,564,453 | 161,840 | 236.8 K to 161.8 K (-31.67 %) |
| Dec 24 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.40 | 75,000 | 1,229,625 | 236,840 | 161.8 K to 236.8 K (+46.34 %) |
| Nov 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.40 | 75,000 | 1,229,625 | 282,508 | |
| Nov 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 74.77 | 38,000 | 2,841,104 | 161,840 | 199.8 K to 161.8 K (-19.02 %) |
| Nov 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 73.90 | 37,000 | 2,734,444 | 199,840 | 236.8 K to 199.8 K (-15.62 %) |
| Nov 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.40 | 75,000 | 1,229,625 | 236,840 | 161.8 K to 236.8 K (+46.34 %) |
| Oct 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.40 | 75,000 | 1,229,625 | 357,508 | |
| Oct 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 69.20 | 2,500 | 172,988 | 161,840 | 164.3 K to 161.8 K (-1.52 %) |
| Oct 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 68.54 | 72,500 | 4,969,012 | 164,340 | 236.8 K to 164.3 K (-30.61 %) |
| Oct 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.40 | 75,000 | 1,229,625 | 236,840 | 161.8 K to 236.8 K (+46.34 %) |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.40 | 87,492 | 1,434,431 | 432,508 | |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 8.01 | 12,508 | 100,127 | 0 | |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 63.11 | 31,385 | 1,980,745 | 161,840 | 193.2 K to 161.8 K (-16.24 %) |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 62.78 | 68,615 | 4,307,444 | 193,225 | 261.8 K to 193.2 K (-26.20 %) |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 8.01 | 12,508 | 100,127 | 261,840 | 249.3 K to 261.8 K (+5.02 %) |
| Sep 25 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.40 | 87,492 | 1,434,431 | 249,332 | 161.8 K to 249.3 K (+54.06 %) |
| Mar 08 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 45.40 | 15,132 | 686,993 | 161,840 | 177 K to 161.8 K (-8.55 %) |
| Mar 08 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 29,000 | 0 | 176,972 | 148 K to 177 K (+19.60 %) |
| Feb 05 2013 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 40.56 | 108,470 | 4,399,543 | 108,470 | |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 29.01 | 360,000 | 10,441,800 | 0 | |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 71,876 | 1,270,408 | 0 | |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 22,624 | 399,879 | 0 | |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 6,246 | 99,998 | 0 | |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 74.31 | 360,000 | 26,751,312 | 73,502 | 433.5 K to 73.5 K (-83.04 %) |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 29.01 | 360,000 | 10,441,800 | 433,502 | 73.5 K to 433.5 K (+489.78 %) |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 74.66 | 100,746 | 7,521,958 | 73,502 | 174.2 K to 73.5 K (-57.82 %) |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 6,246 | 99,998 | 174,248 | 168 K to 174.2 K (+3.72 %) |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 71,876 | 1,270,408 | 168,002 | 96.1 K to 168 K (+74.77 %) |
| Nov 20 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 22,624 | 399,879 | 96,126 | 73.5 K to 96.1 K (+30.78 %) |
| Jul 03 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 29.02 | 733 | 21,271 | 73,502 | 72.8 K to 73.5 K (+1.01 %) |
| Mar 14 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 46.16 | 10,230 | 472,217 | 72,769 | 83 K to 72.8 K (-12.33 %) |
| Mar 14 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 23,100 | 0 | 82,999 | 59.9 K to 83 K (+38.56 %) |
| Jan 30 2012 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 48.59 | 94,000 | 4,567,460 | 94,000 | |
| Mar 17 2011 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 39.79 | 8,115 | 322,896 | 57,101 | 65.2 K to 57.1 K (-12.44 %) |
| Mar 17 2011 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 19,375 | 0 | 65,216 | 45.8 K to 65.2 K (+42.27 %) |
| Jan 24 2011 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 38.17 | 119,000 | 4,542,230 | 119,000 | |
| Aug 26 2010 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 10,000 | 176,750 | 71,876 | |
| Aug 26 2010 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 10,000 | 176,750 | 45,841 | 35.8 K to 45.8 K (+27.90 %) |
| Mar 10 2010 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 47.01 | 11,083 | 521,012 | 35,264 | 46.3 K to 35.3 K (-23.91 %) |
| Mar 10 2010 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 26,000 | 0 | 46,347 | 20.3 K to 46.3 K (+127.78 %) |
| Feb 01 2010 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 47.51 | 87,000 | 4,133,370 | 87,000 | |
| Dec 03 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 31,914 | 564,080 | 81,876 | |
| Dec 03 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 43,086 | 689,807 | 6,254 | |
| Dec 03 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 45.80 | 75,000 | 3,435,143 | 20,347 | 95.3 K to 20.3 K (-78.66 %) |
| Dec 03 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 31,914 | 564,080 | 95,347 | 63.4 K to 95.3 K (+50.31 %) |
| Dec 03 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 43,086 | 689,807 | 63,433 | 20.3 K to 63.4 K (+211.76 %) |
| Oct 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 113,790 | |
| Oct 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 49,340 | |
| Oct 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 44.70 | 30,000 | 1,341,105 | 20,347 | 50.3 K to 20.3 K (-59.59 %) |
| Oct 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 50,347 | 30.3 K to 50.3 K (+65.90 %) |
| Oct 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 30,347 | 20.3 K to 30.3 K (+49.15 %) |
| Jul 10 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 86,618 | |
| Jul 10 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 28,086 | |
| Jul 10 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 44.63 | 30,000 | 1,338,990 | 20,347 | 50.3 K to 20.3 K (-59.59 %) |
| Jul 10 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 50,347 | 30.3 K to 50.3 K (+65.90 %) |
| Jul 10 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 30,347 | 20.3 K to 30.3 K (+49.15 %) |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 153,790 | |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 69,340 | |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 47.96 | 15,400 | 738,586 | 19,868 | 35.3 K to 19.9 K (-43.67 %) |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.83 | 14,600 | 683,736 | 35,268 | 49.9 K to 35.3 K (-29.28 %) |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 49,868 | 29.9 K to 49.9 K (+66.96 %) |
| Apr 07 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 29,868 | 19.9 K to 29.9 K (+50.33 %) |
| Mar 16 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 44.04 | 5,948 | 261,950 | 19,868 | 25.8 K to 19.9 K (-23.04 %) |
| Mar 16 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 13,000 | 0 | 25,816 | 12.8 K to 25.8 K (+101.44 %) |
| Jan 23 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 47.20 | 92,400 | 4,361,280 | 92,400 | |
| Jan 08 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 173,790 | |
| Jan 08 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 79,340 | |
| Jan 08 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 49.86 | 30,000 | 1,495,743 | 12,816 | 42.8 K to 12.8 K (-70.07 %) |
| Jan 08 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 42,816 | 22.8 K to 42.8 K (+87.66 %) |
| Jan 08 2009 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 22,816 | 12.8 K to 22.8 K (+78.03 %) |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 193,790 | |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 89,340 | |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 45.69 | 20,000 | 913,788 | 12,816 | 32.8 K to 12.8 K (-60.95 %) |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 44.97 | 10,000 | 449,747 | 32,816 | 42.8 K to 32.8 K (-23.36 %) |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 42,816 | 22.8 K to 42.8 K (+87.66 %) |
| Oct 08 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 22,816 | 12.8 K to 22.8 K (+78.03 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 213,790 | |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 99,340 | |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.80 | 8,760 | 453,768 | 12,816 | 21.6 K to 12.8 K (-40.60 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.77 | 200 | 10,354 | 21,576 | 21.8 K to 21.6 K (-0.92 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.78 | 11,800 | 611,004 | 21,776 | 33.6 K to 21.8 K (-35.14 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.70 | 2,000 | 103,400 | 33,576 | 35.6 K to 33.6 K (-5.62 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.75 | 2,500 | 129,375 | 35,576 | 38.1 K to 35.6 K (-6.57 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.80 | 3,000 | 155,400 | 38,076 | 41.1 K to 38.1 K (-7.30 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.95 | 200 | 10,390 | 41,076 | 41.3 K to 41.1 K (-0.48 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 52.00 | 1,540 | 80,080 | 41,276 | 42.8 K to 41.3 K (-3.60 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 42,816 | 22.8 K to 42.8 K (+87.66 %) |
| Jul 10 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 22,816 | 12.8 K to 22.8 K (+78.03 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 233,790 | |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 109,340 | |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.50 | 12,500 | 643,750 | 12,024 | 24.5 K to 12 K (-50.97 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.51 | 8,200 | 422,382 | 24,524 | 32.7 K to 24.5 K (-25.06 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.52 | 5,500 | 283,360 | 32,724 | 38.2 K to 32.7 K (-14.39 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 51.60 | 3,800 | 196,080 | 38,224 | 42 K to 38.2 K (-9.04 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 42,024 | 22 K to 42 K (+90.81 %) |
| Apr 14 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 22,024 | 12 K to 22 K (+83.17 %) |
| Mar 19 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Payment of Exercise | F | 47.55 | 5,715 | 271,748 | 12,024 | 17.7 K to 12 K (-32.22 %) |
| Mar 19 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Grant | A | 0.00 | 13,000 | 0 | 17,739 | 4.7 K to 17.7 K (+274.32 %) |
| Feb 01 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | A | 43.15 | 140,000 | 6,041,000 | 140,000 | |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 253,790 | |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 119,340 | |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.70 | 3,000 | 140,100 | 4,739 | 7.7 K to 4.7 K (-38.76 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.74 | 3,000 | 140,220 | 7,739 | 10.7 K to 7.7 K (-27.94 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.75 | 5,000 | 233,750 | 10,739 | 15.7 K to 10.7 K (-31.77 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.77 | 2,000 | 93,540 | 15,739 | 17.7 K to 15.7 K (-11.27 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.80 | 10,000 | 468,000 | 17,739 | 27.7 K to 17.7 K (-36.05 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.81 | 2,000 | 93,620 | 27,739 | 29.7 K to 27.7 K (-6.73 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 46.85 | 5,000 | 234,250 | 29,739 | 34.7 K to 29.7 K (-14.39 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 17.68 | 20,000 | 353,500 | 34,739 | 14.7 K to 34.7 K (+135.69 %) |
| Jan 09 2008 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Buy | M | 16.01 | 10,000 | 160,100 | 14,739 | 4.7 K to 14.7 K (+211.01 %) |
| Oct 10 2007 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 17.68 | 20,000 | 353,500 | 273,790 | |
| Oct 10 2007 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Option Exercise | M | 16.01 | 10,000 | 160,100 | 129,340 | |
| Oct 10 2007 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 41.65 | 1,000 | 41,650 | 4,681 | 5.7 K to 4.7 K (-17.60 %) |
| Oct 10 2007 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 41.61 | 1,000 | 41,610 | 5,681 | 6.7 K to 5.7 K (-14.97 %) |
| Oct 10 2007 | GILD | GILEAD SCIENCES IN ... | YOUNG KEVIN | EVP, Commercial Ope ... | Sell | S | 41.56 | 2,000 | 83,120 | 6,681 | 8.7 K to 6.7 K (-23.04 %) |